Once-monthly ibandronate for postmenopausal osteoporosis: review of a new dosing regimen.

@article{Pyon2006OncemonthlyIF,
  title={Once-monthly ibandronate for postmenopausal osteoporosis: review of a new dosing regimen.},
  author={Eunice Y Pyon},
  journal={Clinical therapeutics},
  year={2006},
  volume={28 4},
  pages={475-90}
}
BACKGROUND Ibandronate, a nitrogen-containing bisphosphonate, was approved by the US Food and Drug Administration (FDA) in May 2003 as a daily oral regimen for the treatment and prevention of post-menopausal osteoporosis. In March 2005, the FDA approved once-monthly dosing with ibandronate for the same indications. OBJECTIVE The purpose of this article was to review the efficacy and tolerability of ibandronate 150 mg once monthly in the treatment and prevention of post-menopausal osteoporosis… CONTINUE READING